ARWR vs REGN · rev $829.4M vs P/E 14, rev $4.29B
Arrowhead Pharmaceuticals Inc (ARWR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ARWR currently screens at market cap $10.59B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ARWR and REGN stock pages for the full models.
Not investment advice.